Table 1.
Site of second malignancy | Age at diagnosis of RCC | Age attained at diagnosis of second primary cancer | ||||
---|---|---|---|---|---|---|
| ||||||
0–29 yrs. | 30–59 yrs. | ≥60 yrs. | 0–29 yrs. | 30–59 yrs. | ≥60 yrs. | |
| ||||||
O(SIR) | O(SIR) | O(SIR) | O(SIR) | O(SIR) | O(SIR) | |
| ||||||
All sites | 23 (6.6)* | 1,232 (1.3)* | 2,540 (1.13)* | 5 (12.02)* | 574 (1.72)* | 3,216 (1.12)* |
All solid tumors | 19 (6.4) | 1,143 (1.32) | 2,258 (1.13) | 5 (16.0) | 533 (1.78)* | 2,882 (1.12)* |
All lymphatic and Hematopoietic diseases | 3 (7.1)* | 72 (1.01) | 223 (1.25)* | 0 (0) | 33 (1.23) | 265 (1.2)* |
Oral cavity and pharynx | 0 (0) | 22 (0.8) | 32 (0.7)* | 0 (0) | 14 (1.04) | 40 (0.63)* p |
Digestive system | 0 (0) | 200 (1.2)b | 518 (1.05) | 0 (0) | 81 (1.4)* k | 637 (1.04) q |
Liver, GB IHBD, EHBD, other biliary | 0 (0) | 22 (1.4)c | 35 (0.93)h | 0 (0) | 12 (2.1)* l | 45 (0.94) r |
Respiratory system | 0 (0) | 188 (1.14) d | 374 (0.97) | 0 (0) | 74 (1.42)* m | 488 (0.98) |
Bones and Joints | 0 (0) | 1 (1.0) | 3 (1.9) | 0 (0) | 0 (0) | 4 (1.9) |
Soft tissue including heart | 0 (0) | 3 90.7) | 12 (1.32) | 0 (0) | 2 (1.0) | 13 (1.13) |
Skin excluding BCC and SCC | 1 (2.9) | 43 (1.2) | 77 (1.24) | 0 (0) | 24 (1.42) | 97 (1.2) |
Breast | 1 (1.4) | 79 (0.8) | 172 (1.05) | 0 (0) | 45 (0.95) | 207 (0.96) |
Female Genital system | 0 (0) | 31 (0.8) | 65 (0.98) | 0 (0) | 16 (0.91) | 80 (0.92) |
Male Genital system | 1 (3.7) | 273 (1.2)*e | 622 (1.2)*i | 0 (0) | 81 (1.5)*n | 815 (1.17)* s |
Urinary bladder | 0 (0) | 44 (0.9) | 198 (1.4)* | 0 (0) | 15 (1.2) | 227 (1.3)* |
Kidney | 14 (170.0)* | 197 (7.6)* | 123 (2.7)* | 5 (1,101)* | 139 (13.6)* | 190 (3.1) |
Renal pelvis | 0 (0) | 4 (2.3) | 1 (0.2)* | 0 (0) | 2 (4.2) | 3 (0.4) |
Ureter | 0 (0) | 2 (1.8) | 8 (2.0) | 0 (0) | 1 (4.2) | 9 (1.8) |
Eye and Orbit | 0 (0) | 3 (2.0) | 2 (0.7) | 0 (0) | 2(3.0) | 3 (0.8) |
Brain and other Nervous system | 0 (0) | 14 (1.21) | 18 (0.91) | 0 (0) | 9 (1.7) | 23 (0.9) |
Endocrine system | 2 (8.1) | 37 (3.4)*f | 31 (2.9)*j | 0 (0) | 27 (4.3)* o | 43 (2.8)* t |
Lymphoma | 3 (9.9)*a | 38 (1.0) | 102 (1.2) | 0 (0) | 18 (1.15) | 125 (1.15) |
Myeloma | 0 (0) | 11 (0.95) | 39 (1.3) | 0 (0) | 7 (1.8) | 43 (1.1) |
Leukemia | 0 (0) | 23 (1.1)g | 82 (1.31)* | 0 (0) | 8 (1.1) | 97 (1.3)* |
Mesothelioma | 0 (0) | 4 (1.7) | 7 (0.93) | 0 (0) | 2 (3.1) | 9 (0.97) |
Kaposi Sarcoma | 1 (10.3) | 0 (0) | 2(1.3) | 0 (0) | 1 (0.5) | 2 (1.1) |
Miscellaneous | 0 (0) | 15 (0.8) | 50 (0.8) | 0 (0) | 6 (0.98) | 59 (0.8) |
p<0.05, O-observed number of cases; SIR- Standardized incidence ratio (ratio of observed to expected number of second malignancies);
Significant increase in the risk of non-lymphocytic lymphomas (SIR:15.1) specifically for nodal type of NHL (SIR: 23.2);
Significant increase in the risk of an SPC in the hepatic flexure of the colon (SIR: 2.4);
Significant increase in the risk of liver cancer (SIR: 1.9);
Significant increased risk of developing cancer of the lung and bronchus (SIR: 1.2);
Significant increase in the risk of cancer of the prostate (SIR: 1.2);
Significant increase in the risk of thyroid cancer (SIR: 3.5);
Significantly increased risk of developing Acute Monocytic leukemia (SIR: 7.3);
Significant increase in risk of pancreatic cancer (SIR: 1.34);
Significant increase in risk of prostate cancer (SIR: 1.2);
Significant increase in the risk of thyroid cancer (SIR: 27) and malignant neoplasms of the adrenal gland (SIR: 7.2);
Significant increase in the risk of SPC in the colon (excluding rectum) (SIR: 1.5);
Significant increase in the risk of an SPC in the liver (SIR: 2.63);
Significant increase in the risk of SPC in the lung and bronchus (SIR: 1.54);
Significant increase in risk of prostate cancer (SIR: 1.5);
Significant increase in the risk of SPC in the thyroid gland (SIR: 4.3);
Significant decrease in the risk of an SPC in the pharynx (SIR: 0.4) and hypopharynx (SIR: 0.16);
Significant increase in the risk of SPC in the hepatic flexure of the colon (SIR: 1.66) ;
Significant increase in the risk of pancreatic cancer (SIR: 1.31);
Significant increase in the risk of prostate cancer (SIR: 1.17);
Significant increase in the risk of thyroid cancer (SIR: 2.9) and cancer of the adrenal gland (SIR: 6.6).